INCY - Incyte Corporation logo

Incyte Corporation

INCY

Incyte Corporation develops and commercializes biopharmaceuticals, focusing on oncology and inflammation. Its key products include JAKAFI for blood cancers, ICLUSIG for leukemia, and PEMAZYRE for biliary tract cancer, sold to pharmacies and hospitals.

βš•οΈ Healthcare NASDAQ Listed 1993 $ USD
$1,000 invested 30 years ago β†’$11,762today

Score Overview

1 Year
Score
Net Growth-68.65%
Net TrendShrank
Net Income Consistencyβ€”
Rev Growth16.91%
Rev TrendGrew
Revenue Consistencyβ€”
5 Years
Score5.6
Net Growth-57.47%
Net Trend40%
Net Income Consistencyβ€”
Rev Growth101.28%
Rev TrendEvery year
Revenue Consistencyβ€”
10 Years
Score
Net Growth287.07%
Net Trend50%
Net Income Consistency
Rev Growth443.61%
Rev TrendEvery year
Revenue Consistency
20 Years
Score5.9
Net Growth7x
Net Trend50%
Net Income Consistency
Rev Growth217x
Rev Trend90%
Revenue Consistency
30 Years
Score
Net Growth61x
Net Trend50%
Net Income Consistency
Rev Growth143x
Rev Trend80%
Revenue Consistency
All Time
Score
Net Growth84x
Net Trend52%
Net Income Consistency
Rev Growth20035x
Rev Trend81%
Revenue Consistency

Explore the 2021 public Archive ranking β†’

Where Incyte Corporation has ranked, year by year

Measure
Fundamentals Window

Showing 10 years ranking history by HDB Score.

Has not reached the top 50 on HDB Score in any year we have ranked.

  • INCY

2004: 95.2% Β· 2021: 57.6% Β· free through 2021 Β· longest runs

Net Income x Stock Price

Historical Returns

Historical Returns
PeriodPriceReturn
Last Price2026-11-17
$ 119.09β€”
1 Year2025-11-17
$ 104.1714.32%
5 Years2021-11-17
$ 65.0283.16%
10 Years2016-11-17
$ 105.5512.83%
20 Years2006-11-17
$ 5.3622x
30 Years1996-11-15
$ 10.1311x
All Time1993-11-04
$ 1.8863x

Prices are split & dividend adjusted. All values are reported in USD.

Fundamental Data

Reported in USD

Year
TTM$ 6.01B$ 403M$ 3.85B
2025$ 5.14B$ 1.28B$ 3.58B
2024$ 4.24B$ 32M$ 2.15B
2023$ 3.69B$ 597M$ 3.65B
2022$ 3.39B$ 340M$ 3.23B
2021$ 2.98B$ 948M$ 2.34B
2020$ 2.66B-$ 295M$ 1.80B
2019$ 2.15B$ 446M$ 2.11B
2018$ 1.88B$ 109M$ 1.43B
2017$ 1.53B-$ 313M$ 1.16B
2016$ 1.10B$ 104M$ 808M
2015$ 753M$ 6M$ 707M
2014$ 511M-$ 48M$ 600M
2013$ 354M-$ 83M$ 509M
2012$ 297M-$ 44M$ 228M
2011$ 94M-$ 186M$ 277M
2010$ 169M-$ 31M$ 424M
2009$ 9M-$ 211M$ 470M
2008$ 3M-$ 178M$ 198M
2007$ 34M-$ 86M$ 256M
2006$ 27M-$ 74M$ 318M
2005$ 7M-$ 103M$ 344M
2004$ 14M-$ 164M$ 469M
2003$ 41M-$ 166M$ 293M
2002$ 95M-$ 136M$ 429M
2001$ 219M-$ 183M$ 507M
2000$ 194M-$ 29M$ 582M
1999$ 157M-$ 26M$ 66M
1998$ 134M$ 3M$ 50M
1997$ 90M$ 6M$ 51M
1996$ 41M-$ 6M$ 7M
1995$ 12M-$ 9M$ 10M
1994-$ 11M$ 6M
IPO1993$ 300K-$ 4M$ 15M
INCY - Incyte Corporation logo

Incyte Corporation fundamental performance

Between 2005 and 2025, revenue grew from $ 7M to $ 5.14B and net income went from -$ 103M to $ 1.28B. Revenue increased in 18 of those 20 years; net income in 10.

Across Incyte Corporation's full reported history, from 1993 to 2025, revenue grew from $ 300K to $ 5.14B and net income went from -$ 4M to $ 1.28B. Revenue increased in 81% of the years measured; net income in 52%.

Incyte Corporation currently holds a 20-year HDB Score of 5.9 out of 10. How the HDB Score is calculated.

Membership

Continue INCY’s history

The public Archive runs through 2021. Membership adds recent and current rankings.

  • Recent and current rankings across 5,187 companies
  • Compare companies with the latest data
  • Track your research shortlist in a portfolio

$149 / year

or $19/month

Continue with Membership

30-day money-back guarantee.

Explore other companies